8-KCorporate ChangesExhibits & Filings

HCA Healthcare, Inc. 8-K Report, Bylaw Amendment (Dec 19, 2022)

Filed December 19, 2022For Securities:HCA

Summary

This 8-K filing from HCA Healthcare, Inc. (HCA) announced an update to the company's bylaws, effective December 19, 2022. The Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee, adopted the Third Amended Bylaws. This amendment primarily focuses on updating provisions related to director nominations and proxy solicitations to align with current regulations, specifically requiring compliance with Rule 14a-19 of the Securities Exchange Act of 1934. While this filing does not contain significant financial information or operational changes, investors should note the proactive steps HCA is taking to ensure its corporate governance practices are up-to-date with regulatory requirements. The changes are described as technical, ministerial, clarifying, and conforming, suggesting a focus on maintaining compliance and good governance rather than a shift in strategic direction or financial performance.

Key Highlights

  • 1HCA Healthcare's Board of Directors adopted amended and restated bylaws (Third Amended Bylaws) effective December 19, 2022.
  • 2The amendments update requirements for director nominations and proxy solicitations.
  • 3A key change is the requirement to comply with Rule 14a-19 under the Securities Exchange Act of 1934 regarding universal proxy.
  • 4The amendments include technical, ministerial, clarifying, and conforming changes to reflect recent updates in Delaware General Corporation Law.
  • 5This filing is primarily procedural and relates to corporate governance, not financial results.
  • 6The Third Amended Bylaws are attached as an exhibit to the 8-K filing.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce that HCA Healthcare's Board of Directors has adopted amended and restated bylaws (Third Amended Bylaws). These changes update corporate governance procedures, specifically concerning director nominations and proxy solicitations.

The key changes involve revising Article II, Section 11 of the bylaws. These revisions update the notification and other requirements for director nominations and proxy solicitations. Notably, the company now requires compliance with Rule 14a-19 under the Securities Exchange Act of 1934, which pertains to universal proxy rules.

Based on the information provided in this 8-K, these bylaw amendments are primarily procedural and related to corporate governance. They do not appear to have an immediate direct financial impact on HCA Healthcare's operations or financial statements. The changes focus on regulatory compliance and governance practices.

The full text of the Third Amended Bylaws, effective December 19, 2022, is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.